# Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

> **NCT06447415** · PHASE1 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** HRS-7450
- **DRUG:** 0.9% sodium chloride injection

## Key facts

- **NCT ID:** NCT06447415
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-06
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-06-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06447415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06447415, "Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06447415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*